What are the specific functions and effects of Besudil/Yilaike and how to show them

Belumosudil mesylate tablets (Belumosudil) is an innovative small molecule targeted drug that is a Rho-related Frizzled Kinase 2 (ROCK2) inhibitor. The drug was originally developed by Kadmon and later acquired by Sanofi for the treatment of chronic graft-versus-host disease (cGVHD). Its pharmacological mechanism is unique and can strike a balance between immune regulation and tissue repair. It is one of the important advances in the current field of immune-related diseases.

The main mechanism of action of Besudil is to inhibit theROCK2 pathway, thereby regulating key immune cell functions. ROCK2 signaling plays a central role in T cell activation and inflammatory responses. When this pathway is overactivated, it can cause the immune system to attack recipient tissues. By selectively inhibiting ROCK2 activity, Besudil reduces the production of inflammatory T cells (such as Th17), while promoting the functional recovery of regulatory T cells (Treg), allowing the immune system to regain tolerance. This dual characteristic of "suppressing inflammation without suppressing immunity" gives it an advantage in treating immune rejection.

Clinically, besudil is used to treat patients with chronic graft-versus-host disease who have failed previous multiple lines of therapy. Its efficacy is not only reflected in reducing skin sclerosis, oral mucosal damage, abnormal liver function and other symptoms, but also improving quality of life and activity ability. Compared with traditional immunosuppressants such as glucocorticoids or calcineurin inhibitors, besudil controls the inflammatory response by regulating signaling pathways and reduces the toxic side effects caused by long-term use.

In addition, the research direction of besudil is gradually expanding from graft-versus-host disease to systemic sclerosis, pulmonary fibrosis and certain autoimmune diseases. The ROCK pathway also plays an important role in tissue fibrosis, so the anti-fibrotic effect of besudil has also become one of the focuses of research. This multiple pharmacological properties make it not only an immunomodulatory drug, but also regarded as a bridge between immunosuppression and anti-fibrotic treatment.

Reference: https://www.drugs.com/pro/rezurock.html